Haider Ups Merck Target to $140, Maintains Buy Rating

Goldman Sachs analyst Asad Haider has maintained his buy rating for Merck & Co, adjusting the target price to $140. This change reflects Haider's continued confidence in the pharmaceutical company's prospects.

Haider's success rate over the past year is impressive, with 84.9% of his ratings resulting in positive returns for TipRanks' virtual portfolio. His average return over this period is a notable 21.7%. These statistics demonstrate Haider's expertise and accuracy as an analyst.